Esperion Therapeutics, Inc. (FRA:0ET)

Germany flag Germany · Delayed Price · Currency is EUR
3.196
+0.097 (3.13%)
At close: Dec 4, 2025
-4.60%
Market Cap 754.86M
Revenue (ttm) 258.93M
Net Income (ttm) -90.20M
Shares Out n/a
EPS (ttm) -0.46
PE Ratio n/a
Forward PE 11.36
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 351
Open 3.196
Previous Close 3.099
Day's Range 3.196 - 3.196
52-Week Range 0.478 - 3.429
Beta n/a
RSI 65.09
Earnings Date Mar 3, 2026

About Esperion Therapeutics

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LD... [Read more]

Industry Pharmaceutical Preparations
Founded 2008
Employees 304
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0ET
Full Company Profile

Financial Performance

In 2024, Esperion Therapeutics's revenue was $332.31 million, an increase of 185.66% compared to the previous year's $116.33 million. Losses were -$51.75 million, -75.27% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.